ArcDia raises EUR 2.7 million to Expand Multianalyte Point-of-Care Respiratory Tract Diagnostic Test

TURKU, Finland, May 9, 2012 /PRNewswire/ –

ArcDia Ltd (http://www.arcdia.fi/eng), the manufacturer of world’s only
multianalyte point-of-care diagnostic system for respiratory tract infections, completed
today EUR 2.7 million funding round to expand its mariPOC(R) diagnostics system. The round
was led by Lifeline Ventures (http://www.lifelineventures.com) with the existing
investors Biothom, Veraventure and private investors participating.

mariPOC(R) diagnoses nine common viruses and bacteria that are clinically important in
respiratory tract infections – such as influenza A/B, RS-virus and parainfluenza 1/2/3
viruses – in a single swab test at point-of-care. The test enables targeted treatment
decisions, saves staff time, provides reliable results rapidly and is economically
feasible for broad diagnostics use. mariPOC(R) is based on the proprietary ArcDia(TM) TPX
detection technology (Nature Biotech 2000:18). mariPOC(R) was launched to the European
market in late 2010, and the product has been in routine clinical use in major hospitals
for more than a year. The first distribution agreement was signed in April with
Laboratories Leti S.L.U., the Spanish market leader in diagnostic testing of
pneumo-respiratory diseases.

“Simply, instead of performing multiple tests that take time to administer and
diagnose, and may be difficult to read, mariPOC(R) provides automated analysis for nine
pathogens in one sample in 20 minutes – and with a clear, readable answer. No other
diagnostics test platform has been able to provide this functionality and
cost-effectiveness to enable respiratory tract infections testing at point-of-care”, says
Dr Aleksi Soini, CEO at ArcDia Ltd.

“Before mariPOC(R), point-of-care multianalyte diagnostic platforms have been too
complicated, expensive, difficult-to-use and inaccurate for respiratory tract
infections.mariPOC(R) is taking into account clinical, economic and scientific mattersto
enable multianalyte diagnostics for this world’s most prevalent disease cluster”, comments
Timo Ahopelto, Founding Partner at Lifeline Ventures.

About ArcDia

Arctic Diagnostics Ltd (http://www.arcdia.fi/eng) has recently launched mariPOC(R),
world’s first multianalyte point-of-care diagnostics test for respiratory tract
infections. Company’s diagnostics test systems have been in use for over 12 months and
performed tens of thousands of tests among the first customers. In the future, the company
will develop additional point-of-care tests based on its proprietary ArcDia(TM) TPX
detection technology (Nature Biotech 2000:18). Earlier this year, ArcDia announced
distribution agreement with Laboratories Leti S.L.U. in Spain, and is currently actively
discussing with distributors in Europe and Asia. More information at

http://www.arcdia.fi/eng

About Lifeline Ventures

Lifeline Ventures (http://lifelineventures.com) is an early stage technology
investor seeking strong science, product innovation and management teams in medical
technology and Web. Lifeline aims at building world-class team of employees, customers,
partners, advisors and investors for the companies it invests in. More information at

http://www.lifelineventures.com

SOURCE ArcDia Ltd